All content for touchPODCAST is the property of touchpodcast and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
touchTALKS for touchONCOLOGY
Listen to Dr Christine Bestvina, as she evaluates the latest data on KRAS mutations in NSCLC and explores how emerging evidence for targeted therapies could influence clinical decision-making.
The expert
Dr Christine Bestvina, University of Chicago, Chicago, IL, USA
This touchPODCAST is for HCPs outside of the UK.
This activity is funded by an independent medical education grant from Revolution Medicines.
This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.
For further information visit our website: www.touchONCOLOGY.com
